• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies

    8/28/25 8:00:00 AM ET
    $FHTX
    $IQV
    $MRNA
    $SANA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $FHTX alert in real time by email

    RESEARCH TRIANGLE PARK, N.C. and CAMBRIDGE, Mass., Aug. 28, 2025 /PRNewswire/ -- IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, and Flagship Pioneering, the bioplatform innovation company, today announced a strategic collaboration to accelerate the development of breakthrough life sciences companies. The collaboration will help the Flagship ecosystem of biopharma companies accelerate innovation by offering access to IQVIA's comprehensive capabilities including unparalleled information assets, analytics and domain expertise across the drug development life cycle from discovery through early development and commercialization.

    (PRNewsfoto/Flagship Pioneering)

    The collaboration will utilize IQVIA's cutting-edge technologies in the areas of artificial intelligence, analytics and clinical trial design and execution to create a more seamless, efficient and effective approach to drug development and early commercial viability for Flagship's ecosystem of companies. The work will center on three service areas: drug development strategy and analytics, clinical development, and asset valuation and due diligence.

    "Working with Flagship Pioneering to foster the development of emerging biopharma companies that will advance the development of life-saving therapies fits squarely within IQVIA's mission to accelerate innovations for a healthier world and bring better treatments to patients faster," said Rob Kotchie, president of Real World Solutions at IQVIA. "We're excited to be a partner to the type of brave and bold thinking at Flagship Pioneering that will secure a healthier and more sustainable future."

    "This collaboration brings enormous value to our platform companies by providing them the potential to greatly expand their reach and impact," said David Khougazian, Executive Partner, Flagship Pioneering. "By using IQVIA's robust data infrastructure and analytics capabilities alongside Flagship's pioneering bioplatforms, this collaboration is poised to positively impact the ability of our companies to accelerate their platform capabilities and drive value creation for life sciences."

    About IQVIA

    IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA's portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI®, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using artificial intelligence responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 88,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.

    IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA's insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures.

    About Flagship Pioneering

    Flagship Pioneering invents and builds bioplatform companies to give each the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than $60 billion in aggregate value. Flagship is operating with $14 billion of assets under management as of its latest capital raise, announced in July 2024. The current Flagship ecosystem comprises over 40 companies, including Foghorn Therapeutics (NASDAQ:FHTX), Moderna (NASDAQ:MRNA), Sana Biotechnology (NASDAQ:SANA), Generate Biomedicines, Inari, Indigo Agriculture, Lila Sciences, Tessera Therapeutics and Valo Health.

    Media Contacts:

    IQVIA:

    Kerri Joseph, IQVIA Investor Relations ([email protected])

    Alissa Maupin, IQVIA Media Relations ([email protected])

    Flagship Pioneering: [email protected] 

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/iqvia-and-flagship-pioneering-announce-strategic-collaboration-to-accelerate-the-development-of-breakthrough-life-sciences-companies-302540186.html

    SOURCE Flagship Pioneering

    Get the next $FHTX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FHTX
    $IQV
    $MRNA
    $SANA

    CompanyDatePrice TargetRatingAnalyst
    Sana Biotechnology Inc.
    $SANA
    7/3/2025$12.00Overweight
    Morgan Stanley
    IQVIA Holdings Inc.
    $IQV
    4/25/2025$160.00Buy → Hold
    HSBC Securities
    Foghorn Therapeutics Inc.
    $FHTX
    4/23/2025$9.00Mkt Outperform
    Citizens JMP
    IQVIA Holdings Inc.
    $IQV
    4/10/2025$170.00Overweight → Equal Weight
    Barclays
    Sana Biotechnology Inc.
    $SANA
    3/18/2025$5.00Mkt Perform → Mkt Outperform
    Citizens JMP
    Sana Biotechnology Inc.
    $SANA
    3/14/2025$7.00Buy
    Jefferies
    Moderna Inc.
    $MRNA
    3/13/2025$40.00Neutral
    Citigroup
    Moderna Inc.
    $MRNA
    2/18/2025$111.00 → $45.00Overweight → Equal Weight
    Barclays
    More analyst ratings

    $FHTX
    $IQV
    $MRNA
    $SANA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley resumed coverage on Sana Biotechnology with a new price target

    Morgan Stanley resumed coverage of Sana Biotechnology with a rating of Overweight and set a new price target of $12.00

    7/3/25 7:51:55 AM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    IQVIA downgraded by HSBC Securities with a new price target

    HSBC Securities downgraded IQVIA from Buy to Hold and set a new price target of $160.00

    4/25/25 8:30:17 AM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Citizens JMP initiated coverage on Foghorn Therapeutics with a new price target

    Citizens JMP initiated coverage of Foghorn Therapeutics with a rating of Mkt Outperform and set a new price target of $9.00

    4/23/25 8:16:18 AM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FHTX
    $IQV
    $MRNA
    $SANA
    SEC Filings

    View All

    Sana Biotechnology Inc. filed SEC Form 8-K: Leadership Update

    8-K - Sana Biotechnology, Inc. (0001770121) (Filer)

    8/29/25 4:11:52 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by IQVIA Holdings Inc.

    SCHEDULE 13G/A - IQVIA HOLDINGS INC. (0001478242) (Subject)

    8/14/25 4:28:07 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 10-Q filed by Sana Biotechnology Inc.

    10-Q - Sana Biotechnology, Inc. (0001770121) (Filer)

    8/11/25 4:10:42 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FHTX
    $IQV
    $MRNA
    $SANA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Bancel Stephane bought $5,004,318 worth of shares (160,314 units at $31.22) (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    3/4/25 4:27:16 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Sagan Paul bought $1,004,251 worth of shares (31,620 units at $31.76) (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    3/4/25 4:24:36 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Danhakl John G bought $255,740 worth of shares (1,275 units at $200.58) (SEC Form 4)

    4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)

    2/7/25 7:03:59 PM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $FHTX
    $IQV
    $MRNA
    $SANA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Mock James M converted options into 1,103 shares and covered exercise/tax liability with 535 shares, increasing direct ownership by 3% to 17,509 units (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    8/29/25 4:13:38 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Legal Officer Klinger Shannon Thyme converted options into 1,103 shares and covered exercise/tax liability with 535 shares, increasing direct ownership by 2% to 28,051 units (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    8/29/25 4:10:00 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President Hoge Stephen covered exercise/tax liability with 991 shares and converted options into 2,048 shares, increasing direct ownership by 0.07% to 1,453,176 units (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    8/29/25 4:06:42 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FHTX
    $IQV
    $MRNA
    $SANA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 30, 2020 - Coronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss Second COVID-19 Vaccine Candidate

    For Immediate Release: November 30, 2020 The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna, Inc. “In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Comm

    11/30/20 5:12:14 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FHTX
    $IQV
    $MRNA
    $SANA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies

    RESEARCH TRIANGLE PARK, N.C. and CAMBRIDGE, Mass., Aug. 28, 2025 /PRNewswire/ -- IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, and Flagship Pioneering, the bioplatform innovation company, today announced a strategic collaboration to accelerate the development of breakthrough life sciences companies. The collaboration will help the Flagship ecosystem of biopharma companies accelerate innovation by offering access to IQVIA's comprehensive capabilities including unparalleled information assets, analytics and domain expertise across the drug development life cycle from discovery through early development and commercial

    8/28/25 8:00:00 AM ET
    $FHTX
    $IQV
    $MRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch
    Biotechnology: Biological Products (No Diagnostic Substances)

    Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

    CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- August 27, 2025 -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in Citi's 2025 Biopharma Back to School Summit, 2025 Wells Fargo Healthcare Conference, and Morgan Stanley 23rd Annual Global Healthcare Conference. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases. Citi's 2025 Biopharma Back to School Summi

    8/27/25 7:00:00 AM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sana Biotechnology to Present at September 2025 Investor Conferences

    SEATTLE, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at four investor conferences in September. The presentations will feature a business overview and update. Sana will present at Citi's 2025 Biopharma Back-to-School Conference at 3:15 p.m. ET on Tuesday, September 2, 2025.Sana will present at the 2025 Wells Fargo Healthcare Conference at 8:00 a.m. ET on Thursday, September 4, 2025.Sana will present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 11:30 a.m. ET on Monday, September 8, 2025.Sana will present

    8/26/25 4:05:00 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FHTX
    $IQV
    $MRNA
    $SANA
    Leadership Updates

    Live Leadership Updates

    View All

    Ajit Singh Appointed CEO of Harbinger Health and CEO-Partner of Flagship Pioneering

    Stephen Hahn to Transition to CEO Emeritus and Special Advisor and remain on Harbinger's board CAMBRIDGE, Mass., Aug. 11, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Harbinger Health, a biotechnology company pioneering the detection of early cancer, today announced the appointment of Ajit Singh, Ph.D. as CEO-Partner of Flagship and the new CEO of Harbinger.  Dr. Singh, a veteran of the diagnostics industry, will also continue as a Harbinger board member, a role he has held since 2024. Dr. Singh succeeds Stephen Hahn, M.D., who will transition from his role as CEO and remain closely involved with the company as CEO Emeritus and Special Advisor. He will co

    8/11/25 12:00:00 PM ET
    $FHTX
    $MRNA
    $SANA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Ted Myles Joins Cellarity as Chief Executive Officer

    Myles, a Biopharma Industry Veteran, Will Also Join Flagship Pioneering as a CEO-Partner CAMBRIDGE, Mass., May 12, 2025 /PRNewswire/ -- Cellarity, a life sciences company transforming the way medicines are created, and Flagship Pioneering, the bioplatform innovation company, today announced the appointment of Ted Myles as Chief Executive Officer of Cellarity and CEO-Partner at Flagship. Myles is a seasoned biopharma leader with deep experience and a track record for building clinical and commercial-stage companies. Previously, he was Chief Financial Officer and Chief Operating

    5/12/25 8:00:00 AM ET
    $FHTX
    $MRNA
    $SANA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors

    CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the election of Neil Gallagher, M.D., Ph.D., and Stuart Duty, to its Board of Directors. "Neil and Stuart are experienced leaders with decades of deep and multifaceted understanding of the biotechnology industry," said Adrian Gottschalk, President and Chief Executive Officer of Foghorn. "We are pleased to welcome them to our Board of Directors and will leverage their strategic insights as we further advance our pipeline." Dr. Gallagher

    5/1/25 7:00:00 AM ET
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FHTX
    $IQV
    $MRNA
    $SANA
    Financials

    Live finance-specific insights

    View All

    Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

    Following FDA input, Seres submitted Phase 2 study protocol to FDA for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat hematological malignancies Seres engaging with multiple parties regarding various deal structures, including potential business development and partnerships, intended to secure capital and other resources to enable the clinical advancement of SER-155 and additional live biotherapeutic product candidates Seres received the $25 million installment payment, as expected, from Nestlé Health Science in July 2025 Conference call at 8:30 a.m. ET today CAM

    8/6/25 7:00:00 AM ET
    $MCRB
    $SANA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    IQVIA Reports Second-Quarter 2025 Results

    Revenue of $4,017 million, up 5.3 percent year-over-year GAAP Net Income of $266 million, Adjusted EBITDA of $910 million GAAP Diluted Earnings per Share of $1.54, Adjusted Diluted Earnings per Share of $2.81 R&D Solutions quarterly bookings of $2.5 billion, representing a book-to-bill ratio of 1.12x R&D Solutions contracted backlog of $32.1 billion, up 5.1 percent year-over-year TAS Revenue of $1,628 million, up 8.9 percent year-over-year Repurchased $607 million of common stock in the quarter, over $1 billion year-to-date IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence

    7/22/25 7:00:00 AM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    IQVIA to Announce Second-Quarter 2025 Results on July 22, 2025

    IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, will announce its second-quarter 2025 financial results before the market opens on Tuesday, July 22, 2025. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. T

    7/1/25 7:00:00 AM ET
    $IQV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $FHTX
    $IQV
    $MRNA
    $SANA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

    SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)

    11/14/24 5:12:32 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

    SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)

    11/14/24 6:00:14 AM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

    SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)

    11/12/24 4:52:24 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care